Pfizer heads into its August 4 earnings event carrying an unusual distinction: short sellers rebuilt aggressively after the July 28 beat, and that positioning has barely softened in the days since.
Short interest tells the most interesting story heading into this print. After spiking 27% in the week through July 28 — as documented in the prior ORTEX note — SI has stabilised near that elevated level, with the latest reading at 3.1% of the free float and the week-on-week change still running at roughly 17%. That is a short base that rebuilt into a post-earnings bounce and has not retreated. The borrow market places no obstacle in front of that trade: availability is extraordinarily loose at over 5,500%, meaning the lending pool is nowhere near constrained. Cost to borrow has eased further to 0.34%, down roughly a third over the past week. This is a deliberate, low-friction short rebuild — not a technical artefact of a tight market. Options pricing corroborates the lack of directional conviction: the put/call ratio at 0.84 is essentially flat against its 20-day average of the same level, with a z-score close to zero. Neither hedgers nor speculators are paying up for insurance.
The analyst debate has been well-established since before the July print and has not shifted materially. The consensus mean target of around $28.75 implies roughly 15% upside from the current $25.01 — meaningful on paper, but the direction of travel in recent weeks was clearly lower, with JPMorgan, BofA, and BMO all trimming targets while holding ratings, and HSBC going further with an outright downgrade to Hold in early July. The bull case rests on a dramatic forward EPS recovery from a depressed post-pandemic base — the 12-month forward earnings growth estimate ranks in the 97th percentile — alongside a dividend yield close to 7% and a $60 billion revenue base anchored by Ibrance and Eliquis. Bears remain focused on gross-to-net adjustments on premium products like Vyndaqel compressing near-term revenue recognition and the structural vulnerability of relying heavily on legacy franchise drugs in a competitive landscape. The PE multiple of roughly 8.6x and EV/EBITDA near 8.2x keep valuation firmly in value territory, not a catalyst in itself.
BlackRock added over 24 million shares through June 30, lifting its stake to 8.7% of shares outstanding. That is a meaningful incremental buy from the largest institutional holder — though passive index mechanics likely explain part of the move, it adds weight to the ownership base at these levels.
August 4's print is therefore less about whether Pfizer can beat a number and more about whether management's commentary on gross-to-net headwinds and the pace of the earnings recovery gives short sellers a reason to hold — or finally cover.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
